Phio Pharmaceuticals Corp. (PHIO)
Stock Price:
$2.63 USD
-0.04 (-1.50%)
Updated Aug 6, 2020 4:00 PM EDT - Market closed
Pre-market: $2.50 -0.13 (-4.94%) Aug 7, 4:07 AM
Key Info
| Market Cap |
15.20M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-9.14M |
| Shares Out |
5.78M |
| EPS (ttm) |
-11.27 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 6, 2020 |
| Last Price |
$2.63 |
| Previous Close |
$2.67 |
| Change ($) |
-0.04 |
| Change (%) |
-1.50% |
| Day's Open |
2.71 |
| Day's Range |
2.60 - 2.72 |
| Day's Volume |
207,774 |
| 52-Week Range |
1.60 - 21.96 |
More Stats
| Market Cap |
15.20M |
| Enterprise Value |
2.36M |
| Earnings Date (est) |
Aug 18, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
5.78M |
| Float |
3.19M |
| EPS (basic) |
-14.609 |
| EPS (diluted) |
-11.27 |
| FCF / Share |
-4.92 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
109,215 |
| Short Ratio |
0.20 |
| Short % of Float |
1.72% |
| Beta |
2.21 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
1.21 |
| Revenue |
n/a |
| Operating Income |
-9.20M |
| Net Income |
-9.14M |
| Free Cash Flow |
-8.73M |
| Net Cash |
12.84M |
| Net Cash / Share |
2.22 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-41.08% |
| ROE |
-77.30% |
| ROIC |
3,378.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (1)
| Buy |
1 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
9.00
Current: $2.63
High
9.00
Target: 9.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Revenue | 0.02 | 0.14 | 0.02 | 0.02 | 0.03 | 0.07 | 0.40 | 0.10 |
| Revenue Growth | -84.78% | 820% | -21.05% | -44.12% | -52.11% | -82.21% | 311.34% | - |
| Gross Profit | 0.02 | 0.14 | 0.02 | 0.02 | 0.03 | 0.07 | 0.40 | 0.10 |
| Operating Income | -8.99 | -7.36 | -14.06 | -9.02 | -10.24 | -8.83 | -20.95 | -12.98 |
| Net Income | -8.91 | -7.36 | -12.45 | -8.99 | -10.22 | -8.80 | -20.93 | -12.88 |
| Shares Outstanding | 0.46 | 0.13 | 0.04 | 0.01 | 0.01 | - | - | - |
| Earnings Per Share | -19.33 | -57.46 | -303.63 | -902.64 | -1,155.12 | -4,345.44 | -15,841.58 | -30,913.09 |
| Operating Cash Flow | -8.65 | -7.52 | -9.51 | -7.76 | -7.32 | -7.76 | -6.31 | -5.06 |
| Capital Expenditures | -0.07 | -0.01 | -0.20 | - | -0.06 | -0.08 | -0.08 | 0.02 |
| Free Cash Flow | -8.72 | -7.53 | -9.72 | -7.76 | -7.37 | -7.84 | -6.39 | -5.04 |
| Cash & Equivalents | 6.98 | 14.93 | 3.63 | 12.96 | 10.67 | 8.55 | 14.44 | 5.18 |
| Total Debt | 0.52 | - | - | - | - | - | - | 0.01 |
| Net Cash / Debt | 6.47 | 14.93 | 3.63 | 12.96 | 10.67 | 8.55 | 14.44 | 5.18 |
| Assets | 8.04 | 15.32 | 4.10 | 13.40 | 11.16 | 9.19 | 14.94 | 5.59 |
| Liabilities | 2.29 | 1.74 | 2.27 | 2.54 | 2.27 | 6.44 | 10.00 | 1.71 |
| Book Value | 5.75 | 13.58 | 1.83 | 10.86 | 8.89 | 2.75 | 4.94 | -5.84 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Phio Pharmaceuticals Corp. |
| Country |
United States |
| Employees |
11 |
| CEO |
Gerrit Dispersyn |
Stock Information
| Ticker Symbol |
PHIO |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: PHIO |
Description
Phio Pharmaceuticals Corp., a biotechnology company, focuses on discovering and developing immuno-oncology therapeutics to treat cancer in the United States. The company's lead product candidate is RXI-109, an sd-rxRNA that reduces the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye. The company also develops Samcyprone, a topical formulation of the small molecule diphenylcyclopropenone for the clearance of common warts; and RXI-231, an sd-rxRNA compound targeting tyrosinase for use as a cosmetic ingredient that enhances the appearance of uneven skin tone and pigmentation. In addition, it develops RXI-109 that reduces the progression of retinal scarring. The company has collaborations with the Gustave Roussy and Medigene AG, as well as with Helmholtz Zentrum München. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.